Arne Slot hasn’t got much wrong during his first season as Liverpool head coach. But this dismal defeat was perhaps a case of the Dutchman holding too much faith in his regular starters.
GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback